LC-MS/MS检测血清25-羟基维生素D替代校准品基质的选择与评价

doi:10.3969/j.issn.1673-8640.2021.02.020

摘要/Abstract

摘要：

目的探讨如何选择和评价液相色谱-串联质谱（LC-MS/MS）检测血清25-羟基维生素D[25（OH）D]替代校准品基质。方法分别用4%牛血清白蛋白（BSA）溶液和30%乙醇水溶液2种替代基质,配制25（OH）D的标准溶液并绘制标准曲线。通过比较内标在不同基质中的响应值差异及基质效应混合实验、准确度验证,对替代基质进行全面的评价。结果内标在4% BSA和血清样本中的响应值差异无统计学意义（P>0.05）,在30%乙醇水溶液和血清样本中的响应值差异有统计学意义（P<0.05）。4% BSA溶液通过了基质效应混合实验验证,30%乙醇水溶液未通过;使用4% BSA基质的标准曲线对室间质量评价样本的定量结果满足准确度要求;30%乙醇水基质未满足要求,有2个样本的定量结果偏移>25%。结论 4% BSA可作为LC-MS/MS检测人血清25（OH）D的替代校准品基质。

关键词: 液相色谱-串联质谱, 血清25-羟基维生素D, 替代校准品基质

Abstract:

Objective To explore the selection and evaluation of a suitable surrogate matrix for preparing 25-hydroxyvitamin D [25（OH）D] calibrators by liquid chromatography tandem-mass spectrometry（LC-MS/MS）. Methods 4% bovine serum albumin（BSA） buffer and 30% ethanol-water were used to prepare 25（OH）D calibrators. They were thoroughly assessed by comparing the peak areas of internal standards in different matrices,testing their matrix effects and accuracy validation. Results There was no significant difference in response between 4% BSA matrix and serum（P>0.05）,while there was statistical difference between 30% ethanol water and serum（P<0.05）. The validation of matrix effect showed that 4% BSA-based calibrator was acceptable,while 30% ethanol-water-based calibrator was not. The external quality assessment（EQA） samples quantified by 4% BSA-based calibrator were well consistent with the target values,but the EQA samples quantified by 30% ethanol-water-based calibrator did not meet accuracy requirements. The bias between the two samples was over 25%. Conclusion 4% BSA can be used as substitute calibrator matrix for the measurement of serum 25（OH）D by LC-MS/MS.

Key words: Liquid chromatography-tandem mass spectrometry, Serum 25-hydroxyvitamin D, Surrogate matrices for calibrators

中图分类号:

R446.1

李冰玲, 程雅婷, 赵蓓蓓, 佘旭辉, 董衡, 余木俊. LC-MS/MS检测血清25-羟基维生素D替代校准品基质的选择与评价[J]. 检验医学, 2021, 36(2): 213-218.

LI Bingling, CHENG Yating, ZHAO Beibei, SHE Xuhui, DONG Heng, YU Mujun. Evaluation of surrogate matrices for serum 25-hydroxyvitamin D calibrators by LC-MS/MS[J]. Laboratory Medicine, 2021, 36(2): 213-218.

图/表 8

参考文献 14

[1]	赵蓓蓓,程雅婷,董衡,等. 25羟基维生素D检测方法的可靠性分析[J]. 临床儿科杂志,2017,35(12):957-960.
[2]	韩吉春,王小臣,李广林,等. 液相色谱-串联质谱法检测干血点样本中25-羟基维生素D2和25-羟基维生素D3[J]. 分析化学,2017,45(3):448-454.
[3]	霍记平,赵志刚. 25(OH)D检测方法的研究进展[J]. 药品评价,2016,13(8):24-26.
[4]	王少亭,李艳. 液相色谱-质谱联用技术在临床检验中的应用与发展[J]. 中华检验医学杂志,2016,39(8):650-653.
[5]	中华医学会检验医学分会,卫生计生委临床检验中心. 液相色谱-质谱临床应用建议[J]. 中华检验医学杂志,2017,40(10):770-779.
[6]	中国医师协会检验医师分会临床质谱检验医学专业委员会. 液相色谱串联质谱临床检测方法的开发与验证[J]. 检验医学,2019,34(3):189-196.
[7]	袁小芬,马金飞,杨青青,等. 液相色谱-串联质谱技术在维生素检测中的应用[J]. 中华检验医学杂志,2019,42(6):479-483.
[8]	BUNCH D R,EL-KHOURY J M,GABLER J,et al. Do deuterium labeled internal standards correct for matrix effects in LC-MS/MS assays? A case study using plasma free metanephrine and normetanephrine[J]. Clin Chim Acta,2014,429:4-5.
[9]	Clinical and Laboratory Standards Institute. Liquid chromatography-mass spectrometry methods;approved guideline. C62-A CLSI,2014.
[10]	周琰,潘柏申. 维生素D检测标准化进程[J]. 检验医学,2016,31(1):71-75.
[11]	程雅婷,董衡,梁晓翠,等. 人血清中25羟基维生素D测定的两种质谱方法比较[J]. 中华临床医师杂志(电子版),2013,7(14):6535-6537.
[12]	王思和,程雅婷,赵蓓蓓,等. 临床色谱质谱检验技术[M]. 北京:人民卫生出版社,2017.
[13]	冯晓杰,杜丽英,冯章英,等. LC-MS/MS法测定人血药浓度的基质效应研究进展[J]. 中国新药杂志,2015,24(13):1488-1492.
[14]	刘晓云,陈笑艳,钟大放. 液相色谱-串联质谱生物分析方法的基质效应和对策[J]. 质谱学报,2017,38(4):388-399.

基质类型	例数	d6-25（OH）D₂/ ×10⁵cps	d6-25（OH）D₃/ ×10⁵cps
4% BSA	7	6.750±0.359	15.000±0.317
30%乙醇水	7	3.700±0.265	8.004±0.609
血清	6	6.580±0.667	15.000±1.080

基质类型	例数	d6-25（OH）D₂/ ×10⁵cps	d6-25（OH）D₃/ ×10⁵cps
4% BSA	7	6.750±0.359	15.000±0.317
30%乙醇水	7	3.700±0.265	8.004±0.609
血清	6	6.580±0.667	15.000±1.080

血清（A）样本编号	A:B/C 混合比例	AB混合样本响应比值				AC混合样本响应比值
血清（A）样本编号	A:B/C 混合比例	可接受范围	平行1	平行2	平行3	可接受范围	平行1	平行2	平行3
A1	3:1	0.179~0.269	0.221	0.217	0.227	0.179~0.268	0.234	0.226	0.216
A2	3:2	0.314~0.471	0.364	0.394	0.368	0.313~0.469	0.409	0.394	0.404
A3	1:1	0.378~0.567	0.469	0.462	0.466	0.377~0.565	0.469	0.476	0.486
A4	2:3	0.396~0.594	0.510	0.482	0.484	0.395~0.592	0.485	0.506	0.514
A5	1:2	0.526~0.789	0.665	0.647	0.670	0.524~0.786	0.771	0.778	0.792^①
A6	2:5	0.533~0.799	0.643	0.669	0.657	0.531~0.796	0.683	0.691	0.665

血清（A）样本编号	A:B/C 混合比例	AB混合样本响应比值				AC混合样本响应比值
血清（A）样本编号	A:B/C 混合比例	可接受范围	平行1	平行2	平行3	可接受范围	平行1	平行2	平行3
A1	3:1	0.179~0.269	0.221	0.217	0.227	0.179~0.268	0.234	0.226	0.216
A2	3:2	0.314~0.471	0.364	0.394	0.368	0.313~0.469	0.409	0.394	0.404
A3	1:1	0.378~0.567	0.469	0.462	0.466	0.377~0.565	0.469	0.476	0.486
A4	2:3	0.396~0.594	0.510	0.482	0.484	0.395~0.592	0.485	0.506	0.514
A5	1:2	0.526~0.789	0.665	0.647	0.670	0.524~0.786	0.771	0.778	0.792^①
A6	2:5	0.533~0.799	0.643	0.669	0.657	0.531~0.796	0.683	0.691	0.665

血清（A）样本编号	A:B/C混合比例	AB混合样本响应比值				AC混合样本响应比值
血清（A）样本编号	A:B/C混合比例	可接受范围	平行1	平行2	平行3	可接受范围	平行1	平行2	平行3
A1	3:1	0.181~0.271	0.239	0.233	0.228	0.194~0.291	0.252	0.242	0.253
A2	3:2	0.292~0.439	0.363	0.362	0.362	0.314~0.471	0.405	0.390	0.408
A3	1:1	0.358~0.536	0.461	0.440	0.431	0.384~0.576	0.506	0.486	0.459
A4	2:3	0.452~0.677	0.614	0.566	0.558	0.484~0.725	0.624	0.610	0.634
A5	1:2	0.495~0.743	0.614	0.608	0.615	0.531~0.796	0.772	0.727	0.739
A6	2:5	0.568~0.852	0.691	0.747	0.758	0.606~0.909	0.783	0.774	0.750